Unresectable HCC
Advertisement
ASCO has issued a companion piece to previously released guidelines addressing commonly asked questions.
A personalized therapeutic cancer vaccine may increase patient response to PD-1 inhibitors.
The study’s primary end points were objective response rate, overall survival, and safety.
Researchers investigated the potential of the phosphatidylserine-targeting antibody bavituximab plus pembrolizumab.
The CheckMate 040 trial reported that nivolumab monotherapy benefits patients who have an acceptable safety profile.
Patients randomly received either TACE plus durvalumab and bevacizumab, TACE plus durvalumab, or TACE alone.
Dr. Brown discussed the results of a retrospective analysis on the addition of radiation to atezolizumab and bevacizumab.
Durvalumab plus bevacizumab with TACE demonstrated significantly improved PFS rates over TACE monotherapy.
In 35 patients, the Eastern Cooperative Oncology Group performance status (ECOG-PS) was 0.
A retrospective review offers insights into the safety and efficacy of adding CDDP to lenvatinib for patients with aHCC.
Of the 1115 patients, 83.2% were male, 49.1% were current or ex-smokers, and 21.4% had consumed alcohol.
Comparing the efficacy of atezo/beva for patients with aHCC who were previously treated with lenva versus no prior treatment.
Drs. Vijayvergia and Lieu conclude with considerations for managing IO-related toxicities in patients with metastatic HCC.
Drs. Vijayvergia and Lieu continue their discussion with attention to biomarkers of response for immunotherapy in mHCC.
Drs. Vijayvergia and Lieu detail the considerations for administering immunotherapy to their patients with metastatic HCC.
Researchers compared the data of patients who underwent salvage hepatectomy and those who received nonsurgical treatment.
Researchers compared the combination therapy with lenvatinib alone.
Patients without microscopic vascular invasion had a better prognosis, and tumor number was found to be associated with pCR.
The study evaluated clinical outcomes associated with lenvatinib after immunotherapy treatment.
Drs. Lieu and Lindquist provide an overview of the patient selection criteria for TACE and TARE in unresectable HCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.